Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | SCN4A | P35499 | 2/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8606916 | 0.82 | POLB (0.49) | POLBADRB2L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL23067928 | 0.81 | IDO1 (0.43) | POLBADRB2CYP1A2CYP2C19CA1 | |
| SCHEMBL104891 | 0.80 | P2RX3 (0.54) | POLBADRB2L3MBTL1CYP1A2CYP2C9 | |
| SCHEMBL6556332 | 0.80 | L3MBTL1 (0.53) | POLBADRB2L3MBTL1MAOAMAOB | |
| SCHEMBL6260397 | 0.79 | POLB (0.50) | POLBADRB2L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL11384408 | 0.78 | CA1 (0.55) | L3MBTL1SLC6A3MAOAMAOBCYP1A2 | |
| SCHEMBL11577753 | 0.78 | ACHE (0.46) | POLBMAOAMAOBCA1CA2 | |
| SCHEMBL18948912 | 0.78 | TDP1 (0.50) | POLBMAOAMAOBMEN1KMT2A | |
| SCHEMBL10601649 | 0.78 | POLB (0.48) | POLBADRB2L3MBTL1MAOAMAOB | |
| SCHEMBL9702616 | 0.78 | P2RX3 (0.53) | POLBADRB2L3MBTL1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026258-B2 | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2011-09-27 | — | — | US | disclosed |
| EP-1661890-B1 | PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | KOWA CO (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20100120845-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-05-13 | — | — | US | disclosed |
| US-7674805-B2 | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-03-09 | — | — | US | disclosed |
| US-20080312262-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-12-18 | — | — | US | disclosed |
| US-7439257-B2 | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2008-10-21 | — | — | US | disclosed |
| EP-1708994-B1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2007-08-08 | — | — | EP | disclosed |
| US-7183295-B2 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20070021424-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
| US-7109226-B2 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20060189667-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1661890-A1 | PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Kowa Co., Ltd. (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-20050101636-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| US-4638070-A | HYPOTENSIVE | CONTINENTAL PHARMA (BE) | 1987-01-20 | — | — | US | disclosed |
| US-4119729-A | TREATMENT OF HYPERTENSION | MEAD JOHNSON & COMPANY (US) | 1978-10-10 | — | — | US | disclosed |
| US-4067904-A | ANTIARRHYTHMIA, HYPOTENSIVE | MEAD JOHNSON & COMPANY (US) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189667-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | PPARA, PPARG, PPARD | POLB 913/4885ADRB2 93/4885L3MBTL1 3044/4885 |
| US-20070021424-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | CMBL, ALK, ALKBH1 | POLB 1721/4885ADRB2 2034/4885L3MBTL1 3924/4885 |
| US-20100120845-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | CMBL, ALK, ALKBH1 | POLB 1721/4885ADRB2 2034/4885L3MBTL1 3924/4885 |
| US-20080312262-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | CMBL, ALK, ALKBH1 | POLB 1721/4885ADRB2 2034/4885L3MBTL1 3924/4885 |
| US-20050101636-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | PPARG, PPARA, PPARD | POLB 2198/4885ADRB2 72/4885L3MBTL1 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.